{"url_path":"/sec/agl/8-k/2026-04-27/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1831097/0001628280-26-027512-index.html","accession_number":"0001628280-26-027512","cik":"0001831097","ticker":"AGL","issuer_name":"agilon health, inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1831097/0001628280-26-027512-index.html","primary_entity_key":"0001831097","primary_entity_name":"agilon health, inc."},"word_count":140,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn April 27, 2026, the Company issued a press release announcing the appointment of Mr. O’Rourke as the Company’s Chief Executive Officer and President and as a director. A copy of the press release is attached hereto as Exhibit 99.1 to this report and is incorporated in this Item 7.01 by reference.\n\nThe information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing."}